Nipro Corporation set to commercialize Infraredx multimodal imaging system in Japan

Jan. 21, 2014
Nipro Corporation, which is the exclusive distributor of Infraredx's TVC Imaging System, has established a manufacturing subsidiary to produce the system commercially.

Nipro Corporation (Osaka, Japan), which is the exclusive distributor of Infraredx's (Burlington, MA) TVC Imaging System, has established a manufacturing subsidiary to produce the system commercially. The TVC Imaging System is a multimodal imaging system that couples near-infrared (NIR) spectroscopy and intravascular ultrasound (IVUS) to help predict the risk of peri-procedural heart attacks by assessing not only the degree of stenosis, but also the presence and extent of lipid core plaques (LCPs).

Related: Intravascular imaging system detects cholesterol signature in heart attack patients

In 2012, the two companies entered into a five-year distribution agreement and are on track to receive regulatory approval from Japan’s Pharmaceuticals and Medical Device Agency (PMDA) this year. In August 2013, Infraredx received a $25 million equity investment from Nipro, and is slated to receive a minimum of $50 million in revenues during the duration of the five-year agreement.

“Japan makes up 50 percent of the worldwide intravascular imaging market, thus representing a significant global growth opportunity for Infraredx,” says Don Southard, president and CEO of Infraredx. “The expansion of manufacturing to Nipro’s new facility boosts our capacity to meet the anticipated demand for the TVC Imaging System in Japan and supports our commercialization efforts in China, Korea, and other emerging Asia Pacific markets.”

IVUS is the standard of care for coronary artery disease in Japan and used to guide more than 80 percent of all percutaneous coronary intervention (PCI) procedures.

The system will be the first of nine products scheduled for commercial manufacturing at the new facility in Yamanashi Prefecture, and the start of production is slated for 2015.


Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Subscribe now to BioOptics World magazine; it's free!

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)

Sponsored Recommendations

Next generation tunable infrared lasers

Nov. 28, 2023
Discussion of more powerful and stable quantum cascade tunable infrared lasers, applications, and test results.

What AI demands mean for data centers

Nov. 28, 2023
The 2023 Photonics-Enabled Cloud Computing Summit assembled by Optica took an aggressive approach to calling out the limitations of today’s current technologies.

SLP feature for lighting control available on cameras offering

Nov. 28, 2023
A proprietary structured light projector (SLP) feature is now available on the company’s camera series, including the ace 2, boost R, ace U, and ace L.

Chroma Customer Spotlight - Dr. David Warshaw, About his Lab

Nov. 27, 2023
David Warshaw, Professor and Chair of Molecular Physiology and Biophysics at the University of Vermont (UVM), walks us through his lab. Learn about his lab’s work with the protein...

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!